All news

What was 2022 like for Celsus?


What was 2022 like for Celsus?

"First, we survived this year" is the most popular phrases one that our team leaders said when we asked them how they remember the outgoing year. This, course, is a joke - and immediately after this phrase, the people talked about other achievements. But the year was really not easy: for example, like many domestic IT companies, we partially switched from already familiar foreign services to Russian ones.

But we still believe that it is not the challenges themselves that are important, but how we deal with them and what results we achieve. Therefore, in this article for ourselves and for everyone who is interested in our project, we want to sum up and tell about the main events.

New direction: the brain CT

This year main events one for us was a new solution launch for analyzing computed tomography for cerebral hemorrhages signs.

The system allows quickly analyzing the brain CT scan for hemorrhagic stroke signs and taking the necessary assistance. We carried out its development with grant support from the FSI. More information can be found on the product page.

The new solution quickly passed calibration testing, becoming the first (and currently the only) service for analyzing brain CT, participating in the Moscow Experiment on the artificial intelligence technologies use in the radiology departments work.

During this time, 8 full-fledged the service new releases have already taken place, and today we have managed to achieve the following metrics: AUC - 0.99, sensitivity - 0.90, accuracy - 0.98, specificity - 0.94. In total, as the experiment part,Celsus  has already analyzed 70 thousand studies for the brain CT analysis!

Product Development

Course, while developing a new direction in diagnostics, we did not forget to work on the “old” ones. Celsus solutions for mammography, fluorography, the chest organs radiography and computed tomography were continuously improved - and this can be easily seen from these solutions metrics growth within the Experiment framework.

These our solutions have repeatedly led the services rating in areas (these ratings are regularly formed by the Experiment organizers).

We continue to work to ensure that Celsus is not only effective, but also convenient to use. Therefore, in 2022, we began developing our own PACS system (medical research repository), as well as a DICOM viewer, with which a doctor can open images, view and edit object markup on it with one click.

We are currently conducting UX testing and working on improving our products. The team's future plans include adding artificial intelligence processing of research to this system (PACS + viewer).

Scientific work

In 2022, Celsus experts took part in the work on several scientific articles.

The first one was prepared jointly with the A.N. Ryzhykh and the National Center for Service Integration experts. It was devoted to the artificial intelligence use in MRI rectal cancer diagnostics. Briefly speaking about the results, the artificial intelligence model developed as the study part showed good accuracy (77.0%), excellent sensitivity (98.1%), but unsatisfactory specificity (45.1%) - that is, it gave too many false positive results.

The article was published in the Russia Coloproctologists Association scientific and practical journal, more details about the study progress and results can be found here.

The second article contains a joint study results by Celsus and the Nizhny Novgorod oncological dispensary a reference mammological center. This study purpose was to evaluate an artificial intelligence-based system application effectivenessfor the mammography studies analysis. The service analyzed 2900 mammography studies that were carried out in medical organizations in Nizhny Novgorod in 2019 and, according to the radiologists’ conclusions, belonged to Bi -RADS classes 1-2 (having a malignant tumor lowest risk).

And again, briefly about the results: in total, the system marked 389 studies as “suspicious”. During them 25 review, the reference center specialists raised the risk category: this means the benign changes presence in them, in which the patient needs to undergo a follow-up mammography in six months. In 2 studies, the malignancy presence was confirmed clinically and radiographically.

The article was published in the scientific journal "The Roszdravnadzor Bulletin", you can read it here (page 45).

Ethics AI Code

The artificial intelligence use ethics question is very important - especially in the medicine conservative field. Without a clear ethical framework, medical AI cannot be truly safe and effective.

Therefore, we consider the Celsus accession to the Ethics National Code in theartificial intelligencefield asthe outgoing year a significant event. In addition to us, three other companies that are developing AI-based products for healthcare have joined the Code.


In 2022, we gained new experience and learned a lot, which means we became stronger and more expert. With this mood, we enter the New Year 2023, in which we will continue to work, invest our bricks in the future medicine building and change the world for the better!

Dear colleagues, friends, doctors and everyone who is interested in our project! The Celsus team sincerely wishes you a Happy New Year. We would like to wish you good health, personal happiness and success in all your endeavors. See you in the new year 2023!